Zentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference

The latest announcement is out from Zentalis Pharmaceuticals ( (ZNTL) ).

Zentalis Pharmaceuticals announced its participation in several investor events, including the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, the TD Cowen’s 6th Annual Oncology Innovation Summit on May 27, 2025, and the Jefferies Healthcare Conference on June 4, 2025. These events will provide Zentalis with opportunities to present its developments and engage with investors, potentially impacting its market presence and stakeholder engagement.

The most recent analyst rating on (ZNTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.

Spark’s Take on ZNTL Stock

According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.

Zentalis Pharmaceuticals faces significant financial hurdles, with consistent losses and negative cash flows. Technical indicators also show weak momentum. However, recent positive clinical developments provide a glimmer of hope for future growth. Despite the financial and technical challenges, the potential of azenosertib in treating aggressive cancers could offer strategic value, albeit with high risk.

To see Spark’s full report on ZNTL stock, click here.

More about Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing small molecule therapeutics for cancer treatment.

Average Trading Volume: 840,828

Technical Sentiment Signal: Strong Sell

Current Market Cap: $89.94M

For detailed information about ZNTL stock, go to TipRanks’ Stock Analysis page.